Showing 6331-6340 of 10817 results for "".
- ARRECTOR: Roflumilast Foam 0.3% Shows Strong Efficacy for Scalp and Body Psoriasishttps://practicaldermatology.com/news/arrector-roflumilast-foam-shows-strong-efficacy-for-scalp-and-body-psoriasis/2474520/A once-daily roflumilast foam formulation significantly improved scalp and body psoriasis in a pivotal phase 3 trial, according to a press release from Arcutis Biotherapeutics, Inc. Researchers for the randomized, double-blin
- Candela Announces GentleMax Pro Integration into Laser Hair Removal Systemhttps://practicaldermatology.com/news/ideal-image-expands-laser-hair-removal-capabilities-with-candelas-gentlemax-pro-plus-and-glx-delivery-system/2474466/Ideal Image has integrated Candela’s latest laser technology—the GentleMax Pro Plus system with the new GLX Delivery System—into select centers across the U.S., according to a Candela news release. The GentleMax Pro Plus syste
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://practicaldermatology.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na
- EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Diseasehttps://practicaldermatology.com/news/early-guselkumab-use-supported-in-pso-patients-with-hbv-cancer-or-heart-disease/2474211/Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovascular disease—according to findings from the EARLY Study.
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://practicaldermatology.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2474320/Laser tattoo removal is increasingly sought by individuals across the globe, according to new research presented at the American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando. The data were presente
- Machine Learning Model Flags HS Up to Two Years Before Diagnosis: Reporthttps://practicaldermatology.com/news/machine-learning-model-flags-hidradenitis-suppurativa-up-to-two-years-before-diagnosis/2474208/A machine learning model analyzing U.S. insurance claims data was able to predict hidradenitis suppurativa (HS) up to two years before formal diagnosis, a new study shows. "Because the individual symptoms of cysts and abscesse
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- Pelthos Therapeutics and Channel Therapeutics to Mergehttps://practicaldermatology.com/news/pelthos-therapeutics-and-channel-therapeutics-to-merge/2474190/Ligand Pharmaceuticals has announced a definitive merger agreement that will combine its wholly owned subsidiary Pelthos Therapeutics with Channel Therapeutics Corporation, forming a publicly traded company under the name Pelthos Therapeutics Inc. The deal is suppo
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J